This includes individuals with a personal or family history of medullary thyroid carcinoma, those with Multiple Endocrine Neoplasia syndrome type 2, patients with type 1 diabetes or diabetic ketoacidosis, anyone currently taking another GLP-1 receptor agonist medication, pregnant or breastfeeding individuals, and patients with active pancreatitis
A third has been diagnosed with obesity and a recent cardiovascular event, so they're on Wegovy specifically
Were talking about 0.5% to 1% volume effect 10 years down the road and that assumes quite significant adoption rates of the drug
Costell M, OConnor JE, Mguez MP, et al
Yeah, I know this is the one peptide that, especially when I was talking with Jay, he was saying this is the one peptide that, you know, people do use topically often because it directly affects the skin